Boston Scientific recently posted a better than expected Q1 performance with a 10% jump in sales, led by strong growth across its segments. The company now includes Neuromodulation in Rhythm Management & Neuro segment, while it was earlier part of the MedSurg segment....
Boston Scientific recently posted a better than expected Q1 performance with a 10% jump in sales, led by strong growth across its segments. The company now includes Neuromodulation in Rhythm Management & Neuro segment, while it was earlier part of the MedSurg segment....
Share this Article
Recommended